2022年11月15日 · Historically lenalidomide plus dexamethasone (Rd) served as reference treatment for patients with newly diagnosed multiple myeloma (NDMM). Lenalidomide, bortezomib, dexamethasone (RVD) has been proposed due to its favourable risk-benefit profile, with data supporting its use in younger patients without intent for frontline transplant.

2021年11月23日 · Among pts with high cytogenetic risk, median PFS was NR for D-RVd and 36.1 months for RVd (10 pts progressed: D-RVd, n=5; RVd, n=5; Figure). In pts ≥65 years, grade 3/4 treatment-emergent adverse events (TEAEs) occurred in 88.9% of D-RVd pts and 77.8% of RVd pts; the most common (≥20%) were neutropenia (37.0%; 29.6%) and lymphopenia (25.9% ...

2024年9月30日 · The addition of daratumumab (Darzalex) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (Dara-RVd) as induction therapy demonstrated improved responses and progression-free and...

2024年9月13日 · Lenalidomide, bortezomib, and dexamethasone (RVd) have previously been established as standard-of-care induction therapy for newly diagnosed multiple myeloma (NDMM).

2020年4月16日 · RVD is an induction regimen that delivers high response rates (VGPR or better) in close to 90% of patients after transplantation, and risk-adapted maintenance can deliver unprecedented long-term outcomes.

Combinations of lenalidomide, bortezomib, and dexamethasone (RVd) are recommended for the treatment of newly diagnosed multiple myeloma (NDMM). 1, 2 Lenalidomide and bortezomib are approved for use in the USA for either transplant-ineligible (TNE) or transplant-eligible (TE) patients with NDMM.

GRIFFIN试验中，达雷妥尤单抗与 来那度胺 、硼替佐米和地塞米松（D-RVd）联合使用提高了适合移植的新诊断多发性骨髓瘤患者巩固治疗结束时的严格意义的完全缓解率。 9月11日，Lancet Haematol在线发表了该试验最终分析的结果，具体内容就和小编一起来看看吧。 达雷妥尤单抗 是一种靶向CD38的单克隆抗体，已被批准与标准治疗方案联合用于治疗新诊断的多发性骨髓瘤（NDMM），并作为单一治疗或与标准治疗方案联合用于复发或难治性多发性骨髓瘤（R/R …

2023年11月2日 · Odds of achieving ≥CR were greater with RVd-alone vs RVd+ASCT in AA pts and were lower for AA vs White pts on the RVd+ASCT arm (panel B). Median PFS (RVd-alone vs RVd+ASCT) was not reached (NR) vs 61.4 mos (HR 1.07) in AA pts and 44.3 vs 67.2 mos (HR 1.67) in White pts.

多发性骨髓瘤（MM）是血液系统第二大常见恶性肿瘤，标准的整体治疗模式及以新药为主的方案极大地改善了MM患者的生存，但微小残留病（MRD）导致大多数患者复发。 因此，需要在传统血清学疗效评估的基础上联合MRD检测，以更精准地评估患者的疾病状态。 目前，二代流式细胞术（NGF）和二代测序（NGS）是基于骨髓样本检测MRD的主流技术。 为使MRD检测标准化和规范化，专家组讨论制订了在MM患者中应用NGF和NGS技术进行骨髓MRD检测的中国专家共识 …

2016年1月22日 · For those treated with dose‐attenuated RVD (n = 34), the outcomes were particularly impressive with overall response rate (ORR), complete remission and very good partial remission (CR + VGPR), and progression‐free survival (PFS) of 94%, 65%, and 36 months, respectively, and overall survival (OS) not reached.